Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-08-23
DOI
10.3389/fphar.2021.580459
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma
- (2019) XiaoMin Wan et al. JAMA Oncology
- Nivolumab plus ipilimumab in non-small-cell lung cancer
- (2019) Martin Reck et al. Future Oncology
- First‐line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non–small cell lung cancer: A United States–based cost‐effectiveness analysis
- (2019) XiaoMin Wan et al. CANCER
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment
- (2018) Pricivel M. Carrera et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
- (2018) Bin Wu et al. Journal for ImmunoTherapy of Cancer
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Mitigating Financial Toxicity Among US Patients With Cancer
- (2017) Jonas A. de Souza et al. JAMA Oncology
- Health state utilities in non-small cell lung cancer: An international study
- (2016) Beenish Nafees et al. Asia-Pacific Journal of Clinical Oncology
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States
- (2015) Jie Ting et al. VALUE IN HEALTH
- Five Years of Cancer Drug Approvals
- (2015) Sham Mailankody et al. JAMA Oncology
- Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting
- (2013) Christos Chouaid et al. Journal of Thoracic Oncology
- Improved curve fits to summary survival data: application to economic evaluation of health technologies
- (2011) Martin W Hoyle et al. BMC Medical Research Methodology
- A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer
- (2011) Bernardo Goulart et al. VALUE IN HEALTH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started